TIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.
Whey Waste Finds New Life as Protein
Latest NewsFrench dairy heavyweight Bel Group has teamed up with Standing Ovation in a bid to transform surplus whey from cheese production into high-value casein proteins using precision fermentation. The collaboration is set to address the longstanding issue of under-utilised acid whey, a by-product that often goes to waste in the dairy sector.
AMT-130 gets FDA breakthrough therapy designation
Latest NewsAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
Netherlands Sets Sights on Global Biotech Leadership
Latest NewsThe Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3 billion in funding.
NLS and Kadimastem: Swiss-israeli merger in ALS
Latest NewsNLS Pharmaceutics secures US$2m equity funding and signs US$25m equity facility to support merger with Kadimastem (Israel) to combine expertise in aiming to become a leader in regenerative medicine in neurodegenerative disorders.
Zürich, 31 March 2025 –
Antimicrobial resistance: Q&A with CARB-X about the fight against AMR
BackgroundCombating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is an industry alliance to support research and development projects in AMR. Since its inception in 2016, CARB-X has supported 114 R&D projects across 14 countries, leading to 18 projects advancing into or completing clinical trials. EBM talked to CARB-X Executive Director Kevin Outterson.
UK Government invests millions into new health data service
Latest NewsUK focuses on digital health research: 600 british pounds (US$764m) for new data platform according to the five recommendations of the Sudlow report.
Reinforcement for Angelini Ventures
AppointmentsDr Regina Hodits joined Angelini Ventures, the VC arm of Angelini Industries, in April as the new Managing Director. She will be based in Germany and lead the company’s international biotech investment strategy with focus Biotech AI and therapeutics.
Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis
Latest NewsTIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.
Menarini and ERBC collaborate
Latest NewsFrench ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.
Switzerland needs more efforts in biomedicine
Latest NewsIn February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential trade conflicts. While other nations are actively collaborating with industry to secure the future of their pharmaceutical sectors, Switzerland is abandoning the only federal initiative aimed at improving conditions for biomedical research. The organisation scienceindustries calls for a renewed effort by the government to develop a new master plan.